JNJ

Janssen gets EC approval for two new indications of Imbruvica
Janssen gets EC approval for two new indications of Imbruvica
Pharmaceutical Business Review
JNJ
Janssen
Europe
Imbruvica
Waldenström’s macroglobulinemia
chronic lymphocytic leukemia
Flag link:
10 Events in Medtech That We Didn’t See Coming This Year
10 Events in Medtech That We Didn’t See Coming This Year
Medical Devices and Diagnostics Industry
devices
Edwards Lifesciences
Boston Scientific
Thrive Earlier Detection
Obalon
Alcon
Abbott Labs
Theranos
JNJ
robotic surgery
Becton Dickinson
FDA
sterlization
Scott Gottlieb
Flag link:
5 Biggest New Drugs Approved in 2019 So Far
5 Biggest New Drugs Approved in 2019 So Far
Motley Fool
drug approvals
FDA
AbbVie
JNJ
Novartis
Pfizer
Skyrizi
psoriasis
Vyndaqel
Zolgensma
SMA
Mayzent
multiple sclerosis
Balversa
metastatic bladder cancer
Flag link:
Eli Lilly's Taltz bests J&J rival Tremfya in head-to-head psoriasis tilt
Eli Lilly's Taltz bests J&J rival Tremfya in head-to-head psoriasis tilt
Fierce Pharma
Eli Lilly
Taltz
JNJ
Tremfya
psoriasis
Flag link:
Deploying Experimental Vaccines Against Ebola
Deploying Experimental Vaccines Against Ebola
Forbes
JNJ
vaccines
ebola virus
Merck
WHO
Flag link:
GSK offloads Ebola vaccines as testing of J&J shot ramps up
GSK offloads Ebola vaccines as testing of J&J shot ramps up
Fierce Biotech
GSK
ebola virus
JNJ
vaccines
Sabin Vaccine Institute
Flag link:
Johnson & Johnson scores latest talc trial win as case count reaches 15,500
Johnson & Johnson scores latest talc trial win as case count reaches 15,500
Fierce Pharma
JNJ
Flag link:
These 5 Prescription Drugs Will Generate a Jaw-Dropping $62.3 Billion in 2024
These 5 Prescription Drugs Will Generate a Jaw-Dropping $62.3 Billion in 2024
Yahoo/Motley Fool
Merck
Keytruda
AbbVie
Humira
Pfizer
Bristol-Myers Squibb
Eliquis
JNJ
Imbruvica
Flag link:
Oklahoma makes final bid to hold J&J responsible for opioid epidemic
Oklahoma makes final bid to hold J&J responsible for opioid epidemic
Yahoo/Reuters
JNJ
opioids
opioid crisis
Oklahoma
Flag link:
FTC investigates J&J contracts regarding the drugmaker's blockbuster Remicade
FTC investigates J&J contracts regarding the drugmaker's blockbuster Remicade
Endpoints
FTC
JNJ
Remicade
antitrust
biosimilars
Pfizer
Inflectra
Flag link:
McKinsey under fire for consulting on opioid sales
McKinsey under fire for consulting on opioid sales
Beckers Hospital Review
McKinsey
JNJ
Purdue Pharma
opioids
opioid crisis
Flag link:
Drugmakers will profit from climate change, Morgan Stanley says
Drugmakers will profit from climate change, Morgan Stanley says
Beckers Hospital Review
climate change
Morgan Stanley
Merck
Sanofi
vaccines
GSK
Takeda
JNJ
Moderna Therapeutics
Flag link:
Janssen’s Ponesimod Finds Success in Head-to-Head Multiple Sclerosis Trial
Janssen’s Ponesimod Finds Success in Head-to-Head Multiple Sclerosis Trial
BioSpace
Janssen
JNJ
ponesimod
Sanofi
Aubagio
relapsing multiple sclerosis
Flag link:
Medtech's Biggest Deals in 2019 ... So Far
Medtech's Biggest Deals in 2019 ... So Far
Medical Devices and Diagnostics Industry
devices
M&A
Hill-Rom
Voalte
Abbott Laboratories
Cephea Valve Technologies
ZOLL Medical
TherOx
Stryker
Arrinex
Medtronic
Epix Therapeutics
Guardant Health
Bellwether Bio
Titan Spine
Bosotn Scientific
Vertiflex
Edward Lifesciences
CAS Medical Systems
Fresenius
NxStage
JNJ
Auris Health
Flag link:
A $100B settlement? Or much less? Opioid payouts a mystery until J&J judge rules
A $100B settlement? Or much less? Opioid payouts a mystery until J&J judge rules
Fierce Pharma
JNJ
Oklahoma
opioids
opioid crisis
Flag link:
Roche and Novo Nordisk Top Clinical Trial Transparency Survey
Roche and Novo Nordisk Top Clinical Trial Transparency Survey
BioSpace
Roche
Novo Nordisk
JNJ
clinical trials
clinical trial transparency
Flag link:
These 5 Firms Could Buy Celgene's Otezla Ahead Of The Bristol Merger
These 5 Firms Could Buy Celgene's Otezla Ahead Of The Bristol Merger
Investors Business Daily
Bristol-Myers Squibb
Celgene
M&A
Otezla
Gilead Sciences
Amgen
Regeneron
Eli Lilly
JNJ
Flag link:
5 Signs of Life in Johnson & Johnson's Second-Quarter Earnings Report
5 Signs of Life in Johnson & Johnson's Second-Quarter Earnings Report
Yahoo/Motley Fool
JNJ
earnings
immunology
devices
Flag link:
J&J warns generics will bite its pharma unit in the second half
J&J warns generics will bite its pharma unit in the second half
Pharmaforum
JNJ
generics
biosimilars
Darzalex
Zytiga
Flag link:
Xarelto falls into the donut hole
Xarelto falls into the donut hole
Biopharma Dive
JNJ
Xarelto
Medicare
Flag link:

Pages